SEC Comment Letter 0000000000-23-007221 to InflaRx N.V. (IFRX)
InflaRx N.V.
Date: July 6, 2023 · CIK: 0001708688 · Accession: 0000000000-23-007221
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-273058
Letter
United States securities and exchange commission logo July 6, 2023 Niels Riedemann Chief Executive Officer InflaRx N.V. Winzerlaer Str. 2 07745 Jena, Germany Re:InflaRx N.V. Registration Statement on Form F-3 Filed June 30, 2023 File No. 333-273058 Dear Niels Riedemann: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Sophia Hudson, P.C.
Show Raw Text
United States securities and exchange commission logo
July 6, 2023
Niels Riedemann
Chief Executive Officer
InflaRx N.V.
Winzerlaer Str. 2
07745 Jena, Germany
Re:InflaRx N.V.
Registration Statement on Form F-3
Filed June 30, 2023
File No. 333-273058
Dear Niels Riedemann:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Sophia Hudson, P.C.